Onco-Innovations Limited has settled $481,694 of outstanding debt by issuing 860,168 common shares to insiders and consultants at a price of $0.56 per share. This transaction involves related parties, including the CEO and CFO, but qualifies for exemptions from certain regulatory approvals due to its size relative to the company's market capitalization. The share issuance is pending final approval from CBOE Canada. This debt settlement helps Onco-Innovations manage liabilities while continuing its focus on cancer research and treatment innovation.
Elizabeth Crain, a director at Core Scientific, has purchased 6,000 shares of the company. This insider buying may indicate her confidence in the company's future prospects. Such moves often attract investor attention as they can signal positive expe...
Hyperscale Data has stopped Bitcoin mining to focus on AI data center services, backed by a $1.2 billion contract at its Michigan facility. The company's assets, including cash and Bitcoin, are worth nearly double its market cap, suggesting undervalu...
Casey's General Stores reported strong Q1 2026 results, surpassing analyst expectations with an EPS of $7.37 versus $6.78 estimated and revenue of $5.68 billion beating the $5.56 billion forecast. Net income rose 27.1% year-over-year to $273.7 millio...
Academy Sports and Outdoors will announce its Q2 2026 earnings on September 9, with revenue expected to rise 3.8% year-over-year to about $1.66 billion. Analysts forecast earnings per share between $2.07 and $2.12, up from $1.94 last year, indicating...
Goldgroup Mining Inc. announced a private placement to raise up to $75 million, with $60 million already committed by major investors including Trafigura and Eric Sprott. The funds will accelerate exploration, advance projects like the San Francisco ...
